BEIJING, CHINA – Media OutReach Newswire – 18 September 2024 – On September 12, the 2024 China International Fair for Trade in Services officially kicked off. The Beijing Economic-Technological Development Area (also known as Beijing E-Town) made a stunning debut in Hall 2 of the Shougang Park with its themed exhibition area. By showcasing cutting-edge innovations like Xiaomi’s SU7, Longwood Valley MedTech’s surgical robot, and the Jielong-3 rocket model, the exhibition serves as a “window” to tell the story of Beijing E-Town’s openness and innovation to visitors from all over the world.

Upon entering the exhibition, visitors are greeted by a naked-eye 3D screen featuring Tiangong robots running forward and Xiaomi’s SU7 speeding ahead, exuding a strong sense of technology and futurism. Outside the exhibition area, New Stone Unmanned Vehicles, widely used in smart scenic areas, parks, commercial streets, universities, and transport hubs, and China’s first certified AI-powered food service robot, which has already been deployed in key commercial buildings in Beijing E-Town, caught the attention of many visitors. People stopped to take photos and examine these technological marvels up close.

As the main hub for high-tech industries in the capital, Beijing E-Town is supported by its “44637” development framework, continuously strengthening four major industries: next-generation information technology, high-end automobiles and new energy vehicles, biotechnology and health, and robotics and intelligent manufacturing. It is also rapidly expanding into six emerging industries, fostering numerous innovative technologies in this fertile ground for industrial development.

At the Beijing E-Town exhibition area, many “E-Town Smart Innovations” serve as ambassadors of the region’s innovation vitality and growth potential, presenting visitors with a series of high-tech business cards. “We hope visitors can experience the vitality of this land, full of dreams and potential, through interactive experiences. We aim to showcase Beijing E-Town as a vibrant, friendly, and livable city that attracts both near and far,” said one of the exhibition staff members.

At the exhibition, Xiaomi’s SU7 has become a popular “check-in spot,” with many visitors lining up for a test ride. Since its official launch in March this year, the Xiaomi SU7 has become a shining star in Beijing E-Town’s automotive supply chain. The Xiaomi Auto Factory, located in Beijing E-Town, has now become a fully functional “smart manufacturing factory” integrating production, research and development, testing, sales, and experience, producing more than 10,000 units per month for three consecutive months.

On another side of the exhibition, the ROPA® AI orthopedic surgery robot was simulating a knee replacement surgery procedure. A staff member from Longwood Valley MedTech explained, “The ROPA® AI orthopedic surgery robot combines ‘smart brain, smart hands, and smart eyes’ to simulate the capabilities of an expert orthopedic surgeon. It can precisely execute individualized surgical plans developed by artificial intelligence before surgery.” Notably, the AIJOINT® 3D surgical simulation software, integrated into ROPA®, is a groundbreaking innovation in the field of orthopedic AI and surgical robotics. With its robust innovation power and leadership in advancing digital orthopedic technology, ROPA® has been awarded an AI-assisted orthopedic treatment Class III medical device registration certificate by the National Medical Products Administration and has also passed certification from the U.S. Food and Drug Administration (FDA). It has been recognized by China’s Ministry of Industry and Information Technology as an “innovation achievement at the international leading level.”

Moreover, multifunctional integrated poles incorporating lighting, traffic indicators, autonomous driving devices, power supply, network, and control functions form the backbone of smart city infrastructure. The Jielong-3 rocket, which set China’s record for the first sea-launched rocket, also made an appearance in model form.

Here, visitors can not only experience cutting-edge technologies and touch the forefront of science but also travel through 30 years of time to deeply understand Beijing E-Town’s “circle of friends.” A “time tunnel” in the exhibition, surrounded by immersive digital images, showcases the development journey of openness and innovation in Beijing E-Town, documenting its long-standing partnerships with enterprises. This includes partnerships spanning 10 years with TPV Technology, JD.com, and Varian Medical Systems; 20 years with Sanofi, Bayer Healthcare, and Yaskawa Shougang Robot; and 30 years with BBAC, GE Healthcare, and SMC.

SMC, the first wholly foreign-owned enterprise in Beijing E-Town, continues to expand its operations and recently laid the foundation for its largest overseas R&D innovation center. GE Healthcare’s Beijing imaging equipment manufacturing base has become the group’s largest medical device production facility worldwide. BBAC has rooted itself in Beijing E-Town, blending “German quality with Chinese manufacturing,” and has reached world-class standards in both manufacturing and operational capabilities.

Zhou Xiaobin, general manager of Qingdao Boruike 3D Manufacturing Co., Ltd., was deeply impressed after visiting the BDA-themed exhibition. “Our company works with partners in Beijing E-Town, and seeing how advanced their surgical robots and commercial aerospace are makes me think about how well it aligns with our 3D printing business. We are now considering setting up a base in E-Town,” he said.

Through this “window,” Beijing E-Town showcases its innovative achievements and development opportunities, conveying its unique charm as a world-class comprehensive industrial city. The door to collaboration is wide open, attracting more high-quality enterprises and projects. As of now, the Beijing Economic-Technological Development Area is home to over 90,000 businesses, including nearly 1,300 foreign-invested enterprises from more than 60 countries and regions. A total of 103 Fortune 500 companies have invested in 158 projects in the area.

Hashtag: #2024ChinaInternationalFairforTradeinServices

The issuer is solely responsible for the content of this announcement.

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

2024 High-Quality Development Promotion Conference Held: Beijing E-Town Extends Global Invitation for Open Collaboration

Corporate News Media OutReach

Sep 18, 2024

BEIJING, CHINA – Media OutReach Newswire – 18 September 2024 – On September 13, the 2024 High-Quality Development Promotion Conference, themed “Invest in E-Town, Create the Future,” took place. Beijing Economic-Technological Development Area (Beijing E-Town, or BDA) showcased its achievements in high-level openness through various segments, including investment promotions, recognition of foreign enterprises, awards for international industrial parks, and signing ceremonies for enterprises entering the E-Town Comprehensive Bonded Zone. These events highlighted E-Town’s strong appeal as a hub for investment and sought to expand its international network for open collaboration.

30 Foreign Enterprises Recognized for Long-Standing Partnership, Boosting Confidence in Foreign Investment

At the event, BDA officials recognized 30 outstanding foreign enterprises that have been partners for 30, 20, and 10 years, respectively. The awards aimed to inspire these companies to increase investment and expand operations. An E-Town official stated, “As the only national-level economic and technological development zone in the capital, Beijing E-Town has consistently prioritized the development of an open economy, continuously enhancing its international business environment standards. E-Town is a fertile ground for win-win cooperation and a magnet for global innovation resources.”

SMC, a world-renowned developer and manufacturer of pneumatic components and one of the awarded “30-Year Outstanding Enterprises,” was Beijing E-Town’s first wholly foreign-owned enterprise. Since its establishment in the area, it has enjoyed national treatment and has now been rooted in E-Town for 30 years. The diverse and high-tech industrial clusters and the thriving innovation ecosystem have encouraged SMC to expand its presence in Beijing E-Town, building several manufacturing units and recently laying the foundation for its largest overseas R&D innovation center. This marks its transformation from a single manufacturing entity into a comprehensive hub for advanced manufacturing and headquarters innovation.

Recently, Bayer Healthcare Company Limited completed its negative list filing for cross-border data transfer in E-Town, becoming the first company in Beijing to achieve data compliance under the Free Trade Zone’s cross-border data transfer policy.

To date, Beijing E-Town has attracted investments from 103 Fortune 500 companies in 158 projects. Of these, one in every four German and British Fortune 500 companies has established a presence in E-Town. Additionally, 46 foreign R&D centers have been recognized in the area, accounting for nearly one-third of the city’s total.

Awards for 10 International Industrial Parks, Providing an International Environment for Foreign Enterprises

The growth of foreign enterprises is closely tied to BDA’s internationalized industrial spaces. The E-Town official stated, “On the path of open development, international parks serve as key platforms for hosting foreign enterprises and projects, forming the foundation for creating an international environment.”

To strengthen the industrial ecosystem and support open development, 10 entities, including Han’s Plaza, Fengchuang Technology Park, Guorui Plaza, Huilongsen Technology Park, and LianDong U Valley Plaza, were awarded the title of “BDA International Industrial Park” at the promotion conference. E-Town will provide these parks with streamlined administrative approvals, government services, and resource access, as well as support for their international transformation.

High-Value Agreements Signed, Building the “Top Choice for Foreign Investment” Brand

At the event, Beijing E-Town signed global cooperation agreements with six international platforms, including the French Chamber of Commerce in China, the German Chamber of Commerce in China, and the Swiss Chamber of Commerce in China. Additionally, Beijing E-Town formalized a strategic partnership with Hurun Report. Rupert Hoogewerf, chairman and chief researcher of Hurun Report, announced plans to release the “Global Gazelle Enterprises” list in Beijing E-Town and establish related startup bases and fund projects. This initiative aims to promote the regional economy and global innovation ecosystem. Furthermore, 21 enterprises intending to enter the E-Town Comprehensive Bonded Zone also signed agreements, jointly advancing high-level openness.

Behind these partnerships lies the sustained release of benefits from open and innovative policies. Beijing E-Town emphasizes customized services, policies, and institutional frameworks, offering a series of activities such as “Finding Markets for Foreign Enterprises,” “Seeking Partners for Foreign Enterprises,” and “Sourcing Resources for Foreign Enterprises.” The “2+X” foreign investment policy and service package continue to be optimized, ensuring “minimal approvals” and “superior services” to smooth the path for foreign companies deepening their presence in the Chinese market. A representative from E-Town added, “We will continue to support foreign enterprises in their development, helping them choose E-Town for market opportunities, expand in E-Town for innovation dividends, and grow stronger through the advantages of openness. Our goal is to establish E-Town as the ‘Top Choice for Foreign Investment’ brand.”

“Beijing E-Town is at a pivotal stage of growth, full of potential and opportunities. We sincerely welcome entrepreneurs from around the world to invest and develop here. We will remain open and inclusive, provide fertile policy ground, nurture industrial ecosystems, and create a market-oriented, law-based, convenient, and international business environment to fully support enterprise development,” said Kong Lei, Deputy Secretary of the Party Working Committee and Director of the E-Town Administrative Committee. In his invitation at the promotion conference, Kong welcomed global enterprises to join hands with Beijing E-Town to share opportunities and achieve mutual success.

Hashtag: #BeijingE-Town

The issuer is solely responsible for the content of this announcement.

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI

CISION PR Newswire

Sep 18, 2024

ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing. Preliminary results from this 12-week study demonstrated that ISM001-055 possesses a favorable safety profile and dose-dependent response in lung function in patients with IPF. ISM001-055’s positive Phase IIa results represent a proof-of-concept success for AI-driven drug discovery.

CAMBRIDGE, Mass., Sept. 18, 2024 /PRNewswire/ — Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055. ISM001-055 is a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary fibrosis (IPF). The study met both its primary endpoint of safety and its secondary efficacy endpoints, demonstrating dose-dependent response in forced vital capacity (FVC), a critical measure of lung function in IPF patients.

Insilico’s proprietary AI platform facilitated ISM001-055’s target identification and molecular design. Its development was recently described in a March 2024 Nature Biotechnology paper, which detailed TNIK’s identification as a novel therapeutic target in IPF and ISM001-055 subsequent design. This comprehensive paper showcased ISM001-055’s preclinical evaluation and positive Phase 0 & Phase I clinical studies justifying this intervention’s potential as a disease-modifying agent for IPF.

ISM001-055’s Phase IIa study(NCT05938920) was a randomized, double-blind, placebo-controlled trial that enrolled 71 patients with IPF across 21 sites in China. Patients were randomized to receive either placebo, 30mg once daily (QD), 30mg twice daily (BID), or 60mg QD for 12 weeks. Patient enrollment was initiated in April 2023, and the last subject’s follow-up visit was completed in August 2024. A parallel Phase IIa(NCT05975983) clinical trial in the U.S. is ongoing and actively enrolling patients.

In this 12-week Phase IIa study, ISM001-055 met its primary endpoint of safety and tolerability across all dose levels.

Positive results were also reported for the secondary efficacy endpoint, wherein a dose-dependent FVC improvement was observed. Patients receiving 60mg QD of ISM001-055 demonstrated the largest improvement in FVC.

Complete topline data will be released at the upcoming medical conference and clinical trial results will be submitted for publication in a peer-reviewed journal.

"These results are very encouraging, particularly the dose-dependent response in FVC. IPF is a devastating disease, and seeing improvements in lung function over just 12 weeks of treatment is a promising indication that ISM001-055 may provide a new therapeutic option for patients. Our Phase IIa in the U.S. is actively recruiting patients," said Toby M. Maher, MD, PhD, a leading expert in interstitial lung disease and an investigator in the trial.

"Last year, I presented a lecture on how generative AI can help with end-to-end drug discovery from disease modeling and target identification to generation of novel drugs with the desired properties and purposing it to a specific disease. I used Insilico’s TRAF2 and NCK-interacting kinase (TNIK) inhibitor as a case study going from 0 to Phase I. The fact that this same drug demonstrated efficacy in addition to safety in a Phase IIa study is extraordinary and represents a true first in this new era of AI-powered drug discovery," said Michael Levitt, PhD, 2013 Nobel Laureate in Chemistry.

"With all the hype that surrounds the potential of generative AI in drug discovery and many other potential applications, it is thrilling see to the dose dependence of ISM001-055 in Insilico Medicine’s phase IIa IPF clinical trial. This is strong evidence that the drug is truly effective and that favorable results will continue to be seen in future trials," said Charles Cantor, PhD, a renowned geneticist and advisor to the company since 2014.

"This is great news for the field of AI for drug discovery. The fact that this molecule is safe and has a dose-dependent response means that there is a green light for further studies. I am hopeful it continues its path to making a difference," said Alan Aspuru-Guzik, PhD, Professor of Chemistry and Computer Science at the University of Toronto and CIFAR AI Chair at the Vector Institute.

"This study result represents a critical milestone in AI-powered drug discovery and in my life to date," said Alex Zhavoronkov, PhD, co-CEO of Insilico Medicine. "While we expected the drug to be safe, we did not expect to see such a clear dose-dependent efficacy signal after such a short dosing period. IPF is a very diverse disease and it is very rare to see improvement in FVC. With our novel TNIK inhibitor, we attempted to go after what we think is a common mechanism in fibrotic diseases and in aging to maximize indication expansion potential."

"I am excited to see that ISM001-055 demonstrated obvious clinical efficacy in IPF patients in only 3-months treatment. While preliminary, this clinical data is certainly encouraging, and provides the clinical validation of AI-powered drug R&D for both novel target and novel molecule," said Feng Ren, PhD, co-CEO and CSO of Insilico Medicine. " This is a significant milestone for Insilico Medicine and the AI driven drug discovery Industry. The milestone is achieved due to the contribution of both the capabilities of our proprietary generative AI platform and the efforts of our multidisciplinary R&D team. We will continue to fully commit to provide breakthrough solutions for the benefit of the patients globally."

Following the positive results from this Phase IIa trial, Insilico Medicine will engage regulatory authorities to discuss the design of a Phase IIb study. The company aims to explore extended treatment durations and larger patient cohorts to further investigate ISM001-055’s therapeutic potential in IPF.

About ISM001-055 and TNIK

ISM001-055 is a potentially first-in-class small molecule targeting TNIK utilizing generative AI. In IPF, the activation of TNIK drives pathological fibrosis in the lungs, contributing to the progressive decline in lung function. By inhibiting TNIK, ISM001-055 aims to halt or reverse fibrotic processes, offering a disease-modifying treatment for patients with IPF. In February 2023, ISM001-055 received Orphan Drug Designation from the FDA for treating Idiopathic Pulmonary Fibrosis.

About the Phase IIa Study

The double-blind, placebo-controlled Phase IIa clinical trial (NCT05938920) evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12-week oral ISM001-055 dosage in 71 subjects with IPF. Patients from 21 sites were randomized into four parallel cohorts: 30mg QD, 30mg BID, 60mg QD, and placebo. Preliminary results from the study show ISM001-055 demonstrated a good safety profile and dose-response trend in lung function in IPF patients.

About Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, scarring lung disease characterized by a progressive and irreversible decline in lung function. Affecting approximately 5 million people worldwide, IPF carries a poor prognosis, with a median survival of 3 to 4 years. Current treatments, including antifibrotic drugs, can slow disease progression but do not stop or reverse it, leaving a significant unmet need for more effective, disease-modifying therapies. IPF is an age-related disease, with the average age of onset typically between 60 and 70 years, and it is most commonly diagnosed in older adults. The disease is rare in individuals under the age of 50.

About Insilico Medicine

Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to assist novel target discovery and the generation of novel molecular structures. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com

Source : Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Beijing E-Town Shines at Cultural Tourism Exhibition with Cutting-Edge Technology

Corporate News Media OutReach

Sep 18, 2024

BEIJING, CHINA – Media OutReach Newswire – 18 September 2024 – At the recent 2024 China International Fair for Trade in Services, the “Cultural Tourism Services” exhibition booth of the Beijing Economic-Technological Development Area (also known as Beijing E-Town) in Hall 9 of the Shougang Park captured attention with its strong “tech vibe.” Covering approximately 136 square meters, the booth was divided into three sections: “Technology Leading Industrial Innovation,” “Technology Creating a Better Life,” and “Technology Empowering Livable Ecology.” With a clever use of an “island-style design” paired with “large screens,” the booth created a panoramic and immersive viewing experience for visitors, showcasing future industry highlights, new industrial-tech cultural tourism plans, and key points of human and ecological landscapes of Beijing E-Town.

A representative from the Beijing Economic-Technological Development Area stated that as the primary platform of the Beijing International Science and Technology Innovation Center’s “Three Cities and One Zone” and a pioneer in the high-quality development of the capital, the BDA has always maintained synergy between industrial development and cultural prosperity. By fostering mutual empowerment between technological innovation and cultural growth, the area is dedicated to creating a “Capital Innovation Culture Leading Zone.” It actively promotes the deep integration of technology, culture, and tourism, striving to build a demonstration area for industrial and technological tourism.

Upon entering the exhibition, visitors were greeted by nearly ten star products from Beijing E-Town, including the EX Robot, Peking Opera Robot, unmanned vending vehicles, AR subtitle glasses, “AI + Education” robots, and drones. The exhibit was further enhanced by a stunning ultra-clear LED screen that spanned the booth. A “digital Liangshui River” flowed beneath visitors’ feet, dynamically displaying shimmering water with clearly visible deer and waterfowl along the banks, creating a fully immersive and tech-filled experience. “It’s both impressive and surprising. I’ve been to Beijing E-Town several times before, but this is my first time ‘walking through’ it in such a way. It truly feels as innovative, tech-savvy, stylish, and livable as it’s being presented,” said Mr. Song, a local resident.

The exhibition also launched various activities, such as the release of the “Beijing E-Town Industrial Tourism Routes” and a guide to popular social media check-in spots, all displayed on electronic screens for easy access by visitors. The tourism route release, themed “A Tech Journey in E-Town,” introduced and recommended routes like “Cutting-Edge Innovation in E-Town,” “Science & Tech Education in E-Town,” “Unmanned Technology in E-Town,” “Learning History Through Action in E-Town,” and “Lohas Leisure in E-Town.” These routes include stops such as the COFCO Coca-Cola (Beijing) Museum, Capital Dairy Science Museum, Xiaomi Auto Super Factory, and the National Intelligent Connected Vehicle Innovation Center.

According to the BDA representative, the industrial tourism routes are part of the “City of Science Museums” initiative, which has already attracted over 100 corporate pavilions, experience centers, and science, technology, and cultural museums to join. This year, the initiative will continue to promote the “Beijing E-Town City of Science Museums” series of activities, providing multi-level, multi-disciplinary, and diverse cultural innovation experiences that offer the public a hands-on encounter with technological innovation.

In addition to showcasing where to explore in the Beijing Economic-Technological Development Area, the booth also introduced ways to visit popular spots. For example, the smart bird monitoring system at the Milu Deer Park was featured, unveiling the mysterious workings of the AI “Bird Inspector.” The Sky Castle Science Education Base also made its debut at the booth, offering visitors a detailed guide to enjoying their visit. Ms. Li, a resident, shared, “As a space enthusiast, I’ve always wanted to visit Sky Castle but have never had the chance. This encounter at the fair has not only given me more insight into the venue but also helped me plan my visit.”

Furthermore, the exhibition showcased “E-Town Gifts,” cultural and creative products with E-Town elements, allowing visitors to take home a unique souvenir from the area. It was announced that the first-ever “E-Town Gifts” city cultural store has officially opened in Hall 3 of the Shougang Park Metaverse Pavilion during the fair. This permanent window offers high-quality gifts and cultural products, including E-Town-themed items, classic Chinese porcelain, colorful Beijing embroidery, Yanjing Eight Wonders, intangible cultural heritage crafts, fine arts, and sports-themed creations, all originating from Beijing and the BDA.

Hashtag: #BeijingETown

The issuer is solely responsible for the content of this announcement.

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

Alef signs mass manufacturing flying car agreement

CISION PR Newswire

Sep 18, 2024

Alef Aeronautics signs a manufacturing agreement with PUCARA Aero and MYC for aviation grade parts for its 3,200 pre-orders

PUCARA Aero and MYC, a joint venture with experience manufacturing aviation grade parts for Boeing and Airbus, signs an agreement to manufacture parts for Alef Alef has secured over 3,200 pre-orders and is now entering agreements for mass production of its Model A flying car

SAN MATEO, Calif., Sept. 18, 2024 /PRNewswire/ — Alef Aeronautics, a sustainable mobility company that is designing and developing a flying car, announced today an agreement with a joint venture between PUCARA Aero and MYC to manufacture aviation grade certifiable parts for Alef’s Model A flying car.

Combined, PUCARA Aero and MYC have manufactured hundreds of different parts for civil and military airplanes, helicopters and drones. The combined services include engine parts, structural assemblies and installation of electrical, hydraulic and avionics systems.

PUCARA Aero proposes to manufacture a subset of aviation grade parts for Alef’s flying car. Parts are planned to be of a high grade and suitable for certification with FAA, EASA and other aviation authorities.

"With a growing number of pre-orders and approaching its final design, Alef began to sign agreements to prepare for mass manufacturing for our Model A car. Safety is our number one priority, so we chose PUCARA Aero and MYC for their impeccable safety record, and compliance with major aviation authorities," said Jim Dukhovny, CEO of Alef.

Alef’s flying car is 100% electric, drivable on public roads and has vertical takeoff and landing capabilities. Alef receives pre-orders through it’s website https://alef.aero

About PUCARA Aero and MYC:

Joint Venture between PUCARA Aero and MYC. PUCARA Aero is the subsidiary in Valencia, Spain of a group with experience manufacturing aviation grade parts for Boeing and Airbus. MYC (Montajes y Cableados Aeronauticos SL) based in Madrid, Spain is experienced in designing, manufacturing and assembling parts and components for Airbus and diverse aeronautical companies in Europe.

About Alef:

Alef, based in San Mateo, CA, is a sustainable electric transportation company designing and developing a road-legal passenger car capable of achieving vertical takeoff and forward flight. Alef recently announced the opening of a new fundraising round. More information can be found at https://alef.aero.

Media Contact: [email protected]
Press Kit: https://alef.aero/press.html

Source : Alef signs mass manufacturing flying car agreement

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Reolink Launches Industry-first 2K 4MP Battery Doorbell, with 1:1 Head-to-Toe View

CISION PR Newswire

Sep 18, 2024

WILMINGTON, Del., Sept. 18, 2024 /PRNewswire/ — Reolink, a renowned smart security solution provider, proudly announces its industry-first Smart 2K 4MP Battery Doorbell with a 1:1 aspect ratio, a powerful addition to its growing lineup of home security solutions. Designed with users’ needs for exceptional performance and convenience, this new battery doorbell features 2K 4MP High-Definition (HD) resolution, an expanded 1:1 head-to-toe view, and dual-band Wi-Fi connectivity. It delivers reliable clarity, coverage, and connectivity, serving as a smart guard right at the doorstep.

Reolink Battery Doorbell

Reolink Battery Doorbell is now available at a MSRP of $145.99 USD and can be purchased in the United States and Europe markets through Reolink.com. It will be available in Australia and Canada starting in October.

Evolving Based on Customer Needs
Following the success of its previous video doorbell PoE model, Reolink recognized customers’ demand for a more flexible, wireless version that also addresses traditional battery doorbell shortcomings. Many existing models with 4:3 or 16:9 aspect ratios and resolutions from 2MP to 8MP, often lack a comprehensive vertical view. Even newer models with improved aspect ratios still face limitations in resolution or field of view. Reolink’s latest Battery Doorbell, overcomes these challenges, offering a solution that meets users’ needs while echoes Reolink’s brand campaign, which emphasizes a commitment to safeguarding and enriching family life through user-centric innovation.

2K 4MP Image with an Expanded Head-to-Toe View
As the industry-first doorbell with a combination of 2K 4MP super HD resolution and a unique 1:1 aspect ratio, the Reolink Battery Doorbell provides an expansive 150°x150°x180° head-to-toe view. This groundbreaking design offers unparalleled visibility of the front door and its surroundings. Day or night, the doorbell with advanced night vision technology captures clear images in 2K HD without blurriness.

Summon Safety at the Doorstep
The Reolink Battery Doorbell features advanced smart detection technology that identifies people, vehicles, and packages, promptly alerting homeowners to any suspicious activity. Its AI package detection feature is particularly useful, providing clear evidence of successful deliveries. In cases of attempted package theft, the doorbell offers real-time monitoring through the Reolink App & Client PC, delivering instant alerts and live view from anywhere. Users can stay informed and in control with real-time notifications and access to both live and recorded footage — all without any subscription fees.

Simplicity from the First Step
Installation is designed for simplicity, enabling users to set up the doorbell within minutes without requiring technical expertise. The device offers easy customization, including chime options, which can be tailored to fit existing setups. Whether integrating with the Reolink Chime, Alexa Echo Show, or Google Assistant, the doorbell complements any home environment. With flexible power options, it can be powered by a rechargeable 7,000mAh battery, providing up to 5 months of operation under typical usage, or hardwired to existing wiring for continuous power, as it is compatible with standard transformers.

Upgraded Connectivity with Dual-Band Wi-Fi
The Reolink Battery Doorbell is equipped with 5GHz and 2.4GHz dual-band Wi-Fi, catering to diverse connectivity needs. The 2.4GHz band provides extensive coverage, ensuring reliable signals for doorbells positioned outside the home, while the 5GHz frequency facilitates rapid network speeds for efficient data transmission.

Trusted Storage, No Monthly Fees
For ample storage, the Reolink Battery Doorbell supports up to a 256GB microSD card. This local storage solution ensures that recordings are securely preserved even during power outages or network disruptions. Additionally, when paired with the Reolink Home Hub, the storage capacity can be extended up to 1TB through two microSD card slots. The doorbell’s robust storage capability offers peace of mind, providing access to crucial video evidence for sharing with law enforcement or for insurance claims, should any suspicious activity or incidents occur.

Key Features:

2K 4MP Head-to-Toe View with 1:1 Aspect Ratio Day & Night Smart Detection with No Subscription Fees Wire-free and Hassle-free Installation Support Existing Wired Mechanical/Digital Chime Multiple Chime Options Dual-band Wi-Fi Network Trusted Local Storage with No Monthly Fees Boost Performance with Reolink Home Hub Two-way Audio with Built-in Mics and A Speaker Enhanced Automation with Smart Home System

To learn more about the Reolink Battery Doorbell, Reolink’s full range of smart home security solutions and services, and insights into Reolink’s brand campaign, visit Reolink.com.

About Reolink

Reolink offers smart security solutions for homes and businesses, aiming for a seamless security experience with its wide range of products. Serving millions globally, it provides video surveillance and protection, standing out for its commitment to security technology innovation. Learn more about Reolink’s offerings at Reolink.com.

Source : Reolink Launches Industry-first 2K 4MP Battery Doorbell, with 1:1 Head-to-Toe View

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Hyundai Motor Group and Rhode Island School of Design Expand Partnership with Launch of New Regeneration Studio

CISION PR Newswire

Sep 18, 2024

Annual research collaboration examines convergence of ecology, bio-design, art and design practices, and future of mobility This year, in the newly launched Regeneration Studio, faculty and students explore the theme of ‘Future Structures’

SEOUL, South Korea and PROVIDENCE, R.I., Sept. 18, 2024 /PRNewswire/ — Hyundai Motor Group and Rhode Island School of Design (RISD) announce the launch of the Regeneration Studio, the latest phase of work in an ambitious multiyear research partnership exploring the relationship between nature, art and design, and the future of mobility.

Hyundai Motor Group designers and engineers working with faculty and staff in RISD’s Edna W. Lawrence Nature Lab in August 2024 (photo credit: Jo Sittenfeld).

Now in its fifth year, the 2024–25 collaboration brings together RISD faculty members and student researchers with Hyundai Motor, Genesis and Kia designers to design around the theme of Future Structures.

The Regeneration Studio, led by an advanced scientific team in RISD’s Edna W. Lawrence Nature Lab, aims to develop entirely new concepts for bio-innovation. This year’s programming comprises a fall biomimicry seminar, spring studio courses and extended research into the summer.

"RISD’s ongoing collaboration with Hyundai Motor Group reflects our shared commitment to fostering a sustainable society and amplifying the expertise and creativity of students, faculty and staff," said RISD President Crystal Williams. "RISD and Hyundai Motor Group are conceiving of future realities that change the way we move through space, understand and use materials, and interpret structures in support of a flourishing and healthy ecological system. We are thrilled to continue investigating the future of mobility with our partners at Hyundai Motor Group, and thank them for their continued investment in this endeavor."

"The Regeneration Studio fosters innovation by integrating nature’s design principles with advanced studio practices, aiming to restore the relationship between humanity and living systems," said SangYup Lee, Head of Hyundai & Genesis Global Design. "Through the Regeneration Studio, this partnership not only advances sustainable design solutions but also lays the foundation for a long-term Sustainable Research Initiative, driving future innovation in mobility and beyond."

"RISD is guided by deep inquiries, generating actionable results that respect principles of design and the world in which they intervene. This mutually respectful dialogue allows us to find answers to industry needs through the study of nature as a generous, inventive, and boundless source of knowledge," said RISD Provost Touba Ghadessi. "Scientists, designers, makers, and visionary colleagues at Hyundai Motor Group and at RISD research biomimicry, regenerative practices, and artificial intelligence to conceive of humans and the planet as an integrated system. In doing so, this ambitious partnership sees the future of mobility as a new paradigm where pragmatic approaches, environmental justice, and creative practice work in harmony."

"Nature doesn’t just inspire — it challenges us to rethink and regenerate," said Karim Habib, Head of Kia Global Design. "By learning from nature’s resilience, we’re discovering new ways to reimagine and shaping a future where human wellness and the planet not only coexist in balance but also move forward together."

Source : Hyundai Motor Group and Rhode Island School of Design Expand Partnership with Launch of New Regeneration Studio

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Bloomage 2024 Mid-Year Report: Driving Growth Through Strategic Transformation to a Solutions Provider

CISION PR Newswire

Sep 18, 2024

PARSIPPANY, N.J., Sept. 18, 2024 /PRNewswire/ — On August 23, 2024, Bloomage released its mid-year financial report, reporting a revenue of RMB 2.811 billion (~USD 385 million) for the first half of the year. This success reflects the company’s strategic transformation from a traditional raw materials supplier to a solution provider, which has driven significant growth across its raw materials and medical terminal products businesses.

Strong Performance in Raw Materials Business

Bloomage’s raw materials segment continues to a core pillar of the company and demonstrate robust performance. In the first half of 2024, the raw materials business achieved a revenue of RMB 630 million (~USD 86 million), an increase of 11.02% year-on-year. Bolstered by its successful globalization strategy, Bloomage’s export sales reached RMB 328 million (~USD 45 million), up by 19.30%. The overall gross profit margin for the raw materials business (excluding Forster) was 70.71%, an increase of 0.51% from the previous year. Notably, the gross profit margin for pharmaceutical-grade hyaluronic acid remained stable at 87.54%, positioning Bloomage among the highest in the industry and demonstrating its strong market competitiveness and profitability.

Strategic Shift to Solution Provider

Building on the solid foundation of its raw materials business, Bloomage is undergoing a strategic transformation from being primarily a raw material supplier to a solution provider. The company’s raw materials have become an integral part of the product lines of many well-known pharmaceutical, personal care, and health food companies. Leveraging its advanced technological capabilities, Bloomage has accelerated the research and development of new raw materials.

The success of its strategic transformation is further reinforced by the increased sales of Bloomage’s hyaluronic acid products and other bioactive substances. This shift marks Bloomage’s steady progress from being a "hyaluronic acid leader" to a more diversified portfolio with diverse range of applications to cement its position as an industry leader in bioactive substance innovations.

Expanding Raw Material Offerings Through Advanced R&D

To support this strategic shift, Bloomage is significantly enhancing its research and development efforts. In addition to hyaluronic acid, the company is prioritizing six major categories of bioactive substances: functional sugars, proteins, peptides, amino acids, nucleotides, and natural active compounds. By actively investing in new raw material development and expanding its bioactive substance matrix, Bloomage aims to seize new market opportunities by offering a more comprehensive solutions to its customers.

Currently, Bloomage is engaged in 95 R&D projects. The company has made significant achievements, including successful pilot production of several innovative products, and the completion of pre-commercial trials for many others.

Accelerating Product Commercialization with advanced Pilot Platform

Bloomage has established a state-of-the-art pilot-scale testing platform, a key asset in accelerating the commercialization of new raw materials. The facility, spanning 30,000 square meters with 64 production lines, is designed to support the pilot and small-scale commercial production of various bioactive raw materials, including pharmaceutical, skincare, and food-grade products. Its flexibility enable efficient switching between different products and processes, significantly accelerating the commercialization of new raw materials, such as enhanced ingredient penetration, skin regeneration, anti-oxidation, anti-aging, and more, which are widely applicable in cosmetics, food, medical aesthetics, and pharmaceuticals.

Moving from research to large-scale production remains as one of the most difficult aspects in commercialization, particularly in scaling up from laboratory conditions to industrial-scale production. In laboratory settings, fermentation tanks may only be 20 liters, but in actual production, they can contain up to several tons. Without the proper environment to conduct thorough large-scale testing, the upscaling process can lead to imprecise conditions like temperature and pH levels that are necessary for optimal microbial growth.

To overcome these challenges, the pilot-scale testing center features a robust pilot production stage. This involves smaller-scale trials before full-scale commercial production where researchers can test and optimize production processes and identify potential issues. This approach minimizes resource waste and excessive cost, ensuring a smoother transition to large-scale production.

Leveraging Raw Material Matrix to Drive Sales Growth

Bloomage leverages its extensive portfolio of bioactive substances to offer comprehensive solutions tailored to customer needs. The company’s raw material solutions matrix supports diverse applications in pharmaceuticals, personal care, nutrition, and innovative business sectors. This diversified offering is essential for meeting the evolving demands of a global client base.

Bloomage’s H1 2024 financial results show that the personal care raw material business continues to grow due to the enhanced solutions offerings. Similarly, the pharmaceutical raw material business is evolving from a single product sales model to a combination of materials and services, while the nutrition and health raw material business is expanding its product matrix through global strategies and partnerships.

Today, Bloomage is not just relying on hyaluronic acid. Supported by six major R&D platforms, the company is constantly innovating and launching new raw materials. By expanding the bioactive substance matrix and enhancing mechanism and application research, Bloomage is poised to develop the next blockbuster ingredient beyond hyaluronic acid.

"Our strategic transformation into a solution provider is driven by our commitment to innovation and investment in advanced research and production capabilities," said Songyan Zou, Vice President of Business Operations at Bloomage. "By expanding our raw material offerings and leveraging cutting-edge technologies, we are well-positioned to meet the diverse needs of our clients and drive sustainable growth."

About Bloomage

Since its founding in 2000, Bloomage has grown into a leading international company specializing in the research, development, production, and sale of hyaluronic acid and other bioactive substances for the cosmetic, functional foods, and pharmaceutical industries. Bloomage’s commitment to quality, innovation, and sustainable innovations have established the company as a trusted name for some of the world’s most renowned brands. It now serves more than 4,000 customers in over 70 countries.

Media Contact:

Cecilia Qian
[email protected]

Source : Bloomage 2024 Mid-Year Report: Driving Growth Through Strategic Transformation to a Solutions Provider

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network